Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
REVUFORJ (REVUMENIB CITRATE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
REVUFORJ
NDA
Get alerts
REVUMENIB CITRATE | N218944 | SYNDAX PHARMACEUTICALS INC
3 strengths
3 unique patents
4 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
3 unique patents, 4 exclusivities by expiration date
All strengths
EQ 25MG BASE
EQ 110MG BASE
EQ 160MG BASE
Active (3)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
Today
10683302
Jun. 8, 2037
11479557
Jun. 8, 2037
12564590
Dec. 18, 2042
NCE
Nov. 15, 2029
ODE-502
Nov. 15, 2031
ODE-504
Nov. 15, 2031
ODE-505
Nov. 15, 2031
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (3)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — EQ 25MG BASE
RLD
3 patents
4 exclusivities
▴
TABLET;ORAL | Approved: Nov 15, 2024
Patents (3)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
10683302
Jun 8, 2037
—
Yes
Yes
—
—
11479557
Jun 8, 2037
—
—
Yes
U-4327
TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE NUCLEOPHOSMIN 1 (NPM1) MUTATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
—
12564590
Dec 18, 2042
—
—
Yes
U-4045
TREATMENT OF RELAPSED OR REFRACTORY ACUTE LEUKEMIA WITH A LYSINE METHYLTRANSFERASE 2A GENE (KMT2A) TRANSLOCATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER
—
Exclusivities (4)
Code
Date
Status
NCE
Nov 15, 2029
Active
ODE-502
Nov 15, 2031
Active
ODE-504
Nov 15, 2031
Active
ODE-505
Nov 15, 2031
Active
#002 — EQ 110MG BASE
RLD
3 patents
4 exclusivities
▾
TABLET;ORAL | Approved: Nov 15, 2024
#003 — EQ 160MG BASE
RLD
3 patents
4 exclusivities
▾
TABLET;ORAL | Approved: Nov 15, 2024